Videos

In the second part of our interview with Christian Lillis, cofounder and CEO of the Peggy Lillis Foundation, he discusses what the passage of the Peggy Lillis Clostridioides difficile Inclusion Act would do for reporting of the infection as well as the potential ancillary effects around antibiotic development and antimicrobial resistance.

In our latest roundtable series, we cover different aspects of HIV care. In this series, clinicians discuss diagnosis, therapies such as long-acting injectables, treating patients with multidrug resistance and more.

In the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.

Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.

Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.

The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.

In part 2 of this interview with Deborah Birx, MD, she highlights that ActivePure Technology provides a continuous decontamination solution that operates independently of manual intervention to reduce HAIs.

Peggy Lillis Foundation CEO Christian Lillis talks about how he became involved in advocacy around C diff and his motivation in helping to bring a bill to Congress to make the healthcare-associated infection a nationally notifiable infectious disease and condition.

Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.

Part 1, Deborah Birx, MD explains photohydrolysis technology provides continuous, automated disinfection of air and surfaces effective in controlling MRSA and improving infection control practices in healthcare settings.

Kate Broderick, PhD, molecular geneticist, discusses the mRNA capping technology and how it helps create stability to mRNA molecules within vaccines and guides them to cells.

In the second episode with Michael Laposata, MD, PhD, he discusses how lab professionals can communicate with infectious disease clinicians, how AI can be used in diagnostics, and potential point-of-care diagnostic opportunities for the lab.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

Here is our inaugural podcast with our host, Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc, who interviews guests on connecting lab professionals to clinicians and the intricacies of assays, the next generation of diagnostics, and the nuances of interpreting test results.

Matthew M Davis, MD, MAPP elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.

Christina Rafferty, BSc, an expert from the CDC, discusses the CLASS assay for swift and accurate detection of Anopheles stephensi, which is essential for controlling malaria spread and protecting communities from resurgence in Africa.

Jared Baeten, MD, PhD emphasizes the importance of the innovative PURPOSE 1 study in the fight against HIV, coinciding with National HIV Testing Day, today serves as a reminder of the ongoing efforts to expand testing access and develop new tools to combat HIV globally.

Jason Roberts, PhD, notes that the BLING study has been a great success for infectious diseases and critical care as a research program, providing strong evidence supporting a meaningful intervention for patients, specifically in clinical cure rates and the occurrence of infections with multiresistant organisms.

Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.

In the last segment of the series, Jones offered his insights for when he considers discharging patients.

In this conversation, Jones discussed concerns around empirical antimicrobial treatment and opportunities to narrow down therapies.

With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.

Bruce Jones, PharmD, FIDSA, BCPS provides commentary on treating challenging patients with comorbidities such as type 2 diabetes, higher BMI, and advanced age.

In the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.

Our experts discuss the potential subgroups who might benefit from the vaccines and their safety profiles.

In part 2 of a 4-part series, clinicians discuss the efficacy, and the mechanism of action of the approved RSV vaccines, including the newly approved Moderna vaccine, mRNA 1345 (mRESVIA).

This is the first in a series of discussions between medical peers around RSV vaccines and specifically the newly approved Moderna RSV vaccine for seniors.

Minnie Hatch was in her late teens when she was diagnosed with the infection. Since then, she has had recurrent episodes and dealt with care challenges along the way.

At Digestive Disease Week, Paul Feuerstadt MD, FACG, AGAF and fellow investigators explore the potential impact of non-antibiotic medications on gut health and their association with recurrent CDI.